Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors

Carcinogenesis

Volumn 34, Issue 12, 2013, Pages 2870-2879

  Nair, Vijayalekshmi ^a   Pathi, Satya ^a   Jutooru, Indira ^a   Sreevalsan, Sandeep ^a   Basha, Riyaz ^b   Abdelrahim, Maen ^b   Samudio, Ismael ^c   Safe, Stephen ^a,d  

^a TEXAS A AND M UNIVERSITY   (United States)

^b M D ANDERSON CANCER CENTER ORLANDO   (United States)

^c PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^d Centre for Translational Cancer Research IBT Texas A and M HSC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CURCUMIN; CYCLIN D1; FATTY ACID SYNTHASE; METFORMIN; MICRORNA; MICRORNA 27A; PROTEIN BCL 2; SURVIVIN; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; TRANSCRIPTION FACTOR SP4; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RNA INTERFERENCE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METFORMIN; PANCREATIC NEOPLASMS; SP TRANSCRIPTION FACTORS;

EID: 84889011636     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt231     Document Type: Article

References (44)

1. Bolen,S. et al. (2007) Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann. Intern. Med., 147, 386-399.
2. Zhou,G. et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest., 108, 1167-1174.
3. Knowler,W.C. et al.; Diabetes Prevention Program Research Group. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med., 346, 393-403.
4. Hinke,S.A. et al. (2007) Methyl succinate antagonises biguanideinduced AMPK-activation and death of pancreatic beta-cells through restoration of mitochondrial electron transfer. Br. J. Pharmacol., 150, 1031-1043.
5. Foretz,M. et al. (2010) Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest., 120, 2355-2369.
6. Sengupta,S. et al. (2010) Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol. Cell, 40, 310-322.
7. Düvel,K. et al. (2010) Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell, 39, 171-183.
8. Shaw,R.J. et al. (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science, 310, 1642-1646.
9. Evans,J.M. et al. (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ, 330, 1304-1305.
10. Libby,G. et al. (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care, 32, 1620-1625.
11. Murtola,T.J. et al. (2008) Antidiabetic medication and prostate cancer risk: a population-based case-control study. Am. J. Epidemiol., 168, 925-931.
12. Wright,J.L. et al. (2009) Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Canc. Causes Contr., 20, 1617-1622.
13. Jiralerspong,S. et al. (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J. Clin. Oncol., 27, 3297-3302.
14. Li,D. et al. (2009) Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology, 137, 482-488.
15. Giovannucci,E. et al. (2010) Diabetes and cancer: a consensus report. CA. Cancer J. Clin., 60, 207-221.
16. Engelman,J.A. et al. (2010) Chemoprevention meets glucose control. Cancer Prev. Res. (Phila)., 3, 1049-1052.
17. Pollak,M. (2010) Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev. Res. (Phila)., 3, 1060-1065.
18. Ben Sahra,I. et al. (2010) Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol. Cancer Ther., 9, 1092-1099.
19. Ben Sahra,I. et al. (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 27, 3576-3586.
20. Yasmeen,A. et al. (2011) Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol. Oncol., 121, 492-498.
21. Zhuang,Y. et al. (2011) Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells. Mol. Cancer Res., 9, 603-615.
22. Gotlieb,W.H. et al. (2008) In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol. Oncol., 110, 246-250.
23. Kim,H.G. et al. (2011) Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation. Br. J. Pharmacol., 162, 1096-1108.
24. Tan,B.K. et al. (2011) Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. J. Clin. Endocrinol. Metab., 96, 808-816.
25. Abdelrahim,M. et al. (2006) Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J. Natl Cancer Inst., 98, 855-868.
26. Chintharlapalli,S. et al. (2007) Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res., 67, 2816-2823.
27. Pathi,S.S. et al. (2011) GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway. Mol. Cancer Res., 9, 195-202.
28. Kim,K. et al. (2012) Identification of oncogenic microRNA-17-92/ZBTB4/ specificity protein axis in breast cancer. Oncogene, 31, 1034-1044.
29. Mertens-Talcott,S.U. et al. (2007) The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res., 67, 11001-11011.
30. Jutooru I.,et al. (2010) Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth. Exp. Cell Res., 316, 2174-2188.
31. Chadalapaka,G. et al. (2008) Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res., 68, 5345-5354.
32. Jutooru,I. et al. (2010) Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein downregulation. J. Biol. Chem., 285, 25332-25344.
33. Jutooru,I. et al. (2010) Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a. Mol. Pharmacol., 78, 226-236.
34. Abdelrahim,M. et al. (2004) Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res., 64, 6740-6749.
35. Abdelrahim,M. et al. (2007) Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res., 67, 3286-3294.
36. Abdelrahim,M. et al. (2005) Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. Mol. Pharmacol., 68, 317-329.
37. Lu,S. et al. (2010) Sp1 coordinately regulates de novo lipogenesis and proliferation in cancer cells. Int. J. Cancer, 126, 416-425.
38. Wang,Y.T. et al. (2008) Sumoylation of specificity protein 1 augments its degradation by changing the localization and increasing the specificity protein 1 proteolytic process. J. Mol. Biol., 380, 869-885.
39. Wei,S. et al. (2009) Thiazolidinediones mimic glucose starvation in facilitating Sp1 degradation through the up-regulation of beta-transducin repeatcontaining protein. Mol. Pharmacol., 76, 47-57.
40. Nonn,L. et al. (2007) Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells. Carcinogenesis, 28, 1188-1196.
41. Jan,H.J. et al. (2009) Rosiglitazone reduces cell invasiveness by inducing MKP-1 in human U87MG glioma cells. Cancer Lett., 277, 141-148.
42. Chen,C.C. et al. (2011) Progesterone receptor inhibits proliferation of human breast cancer cells via induction of MAPK phosphatase 1 (MKP-1/ DUSP1). J. Biol. Chem., 286, 43091-43102.
43. Kisfalvi,K. et al. (2009) Metformin disrupts crosstalk between G proteincoupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res., 69, 6539-6545.
44. Siegel,R. et al. (2012) Cancer statistics, 2012. CA. Cancer J. Clin., 62, 10-29.